Mesa Laboratories stock reports 1.00 percent Q1 revenue growth

Published on 09/30/2026 at 20:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Mesa Laboratories stock was at EUR 115.00 after a minus 0.43 percent session versus EUR 115.50. Q1 fiscal 2027 revenue reached USD 60.14 million, up 1.00 percent year over year.

MLAB, US59064R1095, Illustration mit AI erstellt.

Mesa Laboratories (ISIN US59064R1095) was trading at EUR 115.00 at Lang & Schwarz on September 30, 2026 at 8:39 p.m. CEST, down 0.43 percent versus the prior close of EUR 115.50. The latest quarter delivered USD 60.14 million in revenue, up 1.00 percent year over year, while diluted EPS fell 42.35 percent to USD 0.49, according to StockMarketCap on August 10, 2026.

Q1 revenue edges higher

Mesa Laboratories generated USD 2.83 million in net income in Q1 fiscal 2027, down 40.32 percent from the prior-year quarter, while operating income reached USD 7.03 million, according to StockMarketCap. The figures show a narrow revenue gain alongside weaker per-share earnings, keeping profitability more important than sales growth in the next reporting cycle.

The company operates across sterilization and disinfection control, clinical genomics, biopharmaceutical development and calibration solutions. Its products serve regulated healthcare, laboratory and pharmaceutical processes, giving recurring compliance demand a central role in the business model.

Analyst target stays below Nasdaq quote

MarketBeat reported that Wells Fargo raised its Mesa Laboratories target from USD 94.00 to USD 110.00 on August 14, 2026, while retaining an Equal Weight rating. The same report put the analyst consensus at Hold with a USD 110.00 target, a level below the USD 130.38 Nasdaq quote recorded on September 30, 2026 at 2:44 p.m. EDT.

The USD 110.00 target contrasts with a market capitalization of USD 729.6 million and a 52-week Nasdaq range of USD 66.52 to USD 138.66. That gap makes the next earnings update a key test of whether the recent valuation can be supported by faster earnings growth.

Next results date is November 5

Yahoo Finance lists November 5, 2026 as Mesa Laboratories' next earnings date. The scheduled report follows a quarter in which revenue increased by 1.00 percent year over year, while diluted EPS declined by 42.35 percent.

After hours quote points lower

Mesa Laboratories was trading at EUR 115.00 at Lang & Schwarz on September 30, 2026 at 8:39 p.m. CEST, down 0.43 percent versus the prior close of EUR 115.50. The company is listed on NASDAQ under ticker MLAB and operates in the healthcare sector, specifically medical specialties.